ALZN
Alzamend Neuro, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.31
+0.38%Next report
Analyst consensus
- Next report date
- Dec 8, 2026
- EPS estimate
- -$0.23
- Revenue estimate
- —
Latest reported
- Last report date
- Sep 10, 2026
- EPS actual
- -$0.68
- EPS estimate
- -$0.56
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +24.6%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $26
- PT range
- $26 – $26
- Analysts
- 2
2 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Sep 10, 2026 | -$0.56 | -$0.68 | Miss -21.43% | — |
| Mar 11, 2026 | -$0.53 | -$0.58 | Miss -9.43% | — |
| Dec 9, 2025 | -$0.83 | -$0.30 | Beat 63.86% | — |
| Sep 10, 2025 | -$3.69 | -$1.28 | Beat 65.31% | — |
| Mar 10, 2025 | -$2.61 | -$1.71 | Beat 34.48% | — |
| Dec 11, 2024 | -$21 | -$3.60 | Beat 83.19% | — |
| Sep 11, 2024 | -$2.38 | -$11 | Miss -372.69% | — |
| Dec 15, 2023 | -$0.67 | $40 | Beat 6010.45% | — |
| Sep 13, 2023 | -$47 | -$54 | Miss -14.29% | — |
| Mar 15, 2023 | -$0.04 | -$0.06 | Miss -50.00% | — |
| Dec 12, 2022 | -$0.02 | -$0.03 | Miss -25.00% | — |
| Sep 13, 2022 | -$0.07 | -$0.03 | Beat 57.14% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Dec 8, 2026